3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase NA
1
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Breast Neoplasms
1888
Carcinoma, Non-Small-Cell Lung
1348
Prostatic Neoplasms
980
Colorectal Neoplasms
851
Multiple Myeloma
741
Leukemia, Myeloid, Acute
725
Neoplasms
691
Lung Neoplasms
679
Neoplasm Metastasis
642
Lymphoma
579
Carcinoma, Hepatocellular
571
Pancreatic Neoplasms
566
Stomach Neoplasms
522
Leukemia
511
Recurrence
493
Leukemia, Lymphocytic, Chronic, B-Cell
459
Precursor Cell Lymphoblastic Leukemia-Lymphoma
452
Melanoma
451
Lymphoma, Non-Hodgkin
442
Ovarian Neoplasms
426
Lymphoma, Large B-Cell, Diffuse
423
Squamous Cell Carcinoma of Head and Neck
416
Myelodysplastic Syndromes
416
Head and Neck Neoplasms
403
Brain Neoplasms
403
Rectal Neoplasms
397
Glioblastoma
375
Carcinoma, Renal Cell
350
Hodgkin Disease
338
Esophageal Neoplasms
337
Interventions
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Decitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
OTHER
×
Congenital Bone Marrow Failure Syndromes
×
Clear all
NCT05796570
2026-03-19
MORE
Dana-Farber Cancer Institute
Phase 2
Recruiting
37 enrolled